NASDAQ:VERU - Veru Stock Price, Forecast & News

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VERU shares have decreased by 3.1% and is now trading at $3.10. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru.

Veru is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Veru.

Veru Inc (NASDAQ:VERU) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The company had revenue of $10.58 million for the quarter, compared to analyst estimates of $9.30 million. Veru had a negative net margin of 36.58% and a negative return on equity of 40.45%. View Veru's earnings history.

3 brokerages have issued 1 year target prices for Veru's stock. Their forecasts range from $6.00 to $12.00. On average, they expect Veru's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price. View analysts' price targets for Veru.

Headlines about VERU stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Veru earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutVeru.

Veru saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 365,000 shares, a decrease of 5.2% from the February 27th total of 385,100 shares. Based on an average trading volume of 363,300 shares, the short-interest ratio is presently 1.0 days. Currently, 0.8% of the shares of the stock are short sold. View Veru's Current Options Chain.

Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Prestige Consumer Healthcare (PBH), Inter Parfums (IPAR), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Medifast (MED), Revlon (REV) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Genocea Biosciences (GNCA), Opko Health (OPK), NovaBay Pharmaceuticals (NBY), Rigel Pharmaceuticals (RIGL), Strongbridge Biopharma (SBBP), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vascular Biogenics (VBLT) and Viking Therapeutics (VKTX).

Veru trades on the NASDAQ under the ticker symbol "VERU."

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VERU stock can currently be purchased for approximately $3.10.

Veru has a market capitalization of $202.10 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe. View additional information about Veru.

The official website for Veru is http://www.veruhealthcare.com/.

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]